4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know
AbbVie (ABBV) reached $187.12 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.
4 Reasons To Buy AbbVie
I maintain my Buy rating on AbbVie, emphasizing its medium-to-long-term potential despite recent outlook downgrades and tariff risks. Recent guidance cuts are minor and don't meaningfully undermine the investment case; with earnings growth expected in Q2 2025. The company's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time.
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
The latest trading day saw AbbVie (ABBV) settling at $190.58, representing a +2.25% change from its previous close.
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
Here's How to Play AbbVie Stock as it Reaches Golden Cross
ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.
